Alternative Data for Viatris
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 362 | Sign up | Sign up | Sign up |
| Sentiment | 97 | Sign up | Sign up | Sign up |
| Webpage traffic | 94,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Instagram Followers | 12,273 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 7 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,773 | Sign up | Sign up | Sign up |
| X Followers | 8,488 | Sign up | Sign up | Sign up |
| X Mentions | 39 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 3,590 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 59 | Sign up | Sign up | Sign up |
| Linkedin Employees | 17,652 | Sign up | Sign up | Sign up |
About Viatris
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia.
| Price | $14.08 |
| Target Price | Sign up |
| Volume | 8,863,382 |
| Market Cap | $16.3B |
| Year Range | $8.47 - $16 |
| Dividend Yield | 3.3% |
| PE Ratio | 223.2 |
| Analyst Rating | 0% buy |
| Industry | Drug Manufacturers |
In the news
 |
Viatris Inc. Stock Nears 52-Week High Ahead of Q4 Earnings: Shares Climb on Pipeline StrengthFebruary 25 - Ibtimes.com.au |
 |
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of PresbyopiaFebruary 24 - Yahoo |
Viatris Says FDA Accepts For Review sNDA For MR-141 For Treatment Of Presbyopia; FDA PDUFA Goal Date Set For October 17February 24 - Benzinga |
|
|
Earnings To Watch: Viatris (VTRS) Reports Q4 Results TomorrowFebruary 24 - Yahoo |
|
Will UBS Upgrade And Inpefa’s First Global Launch Change Viatris' (VTRS) Narrative?February 23 - Yahoo |
|
Unveiling Viatris (VTRS) Q4 Outlook: Wall Street Estimates for Key MetricsFebruary 22 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 3.76B | 2.38B | 1.38B | -128M | 800M | 0.670 |
| Q2 '25 | 3.58B | 2.25B | 1.33B | -4.6M | 578M | 0.620 |
| Q1 '25 | 3.25B | 2.09B | 1.16B | -3.04B | -2.32B | 0.500 |
| Q4 '24 | 3.53B | 2.31B | 1.22B | -517M | 340M | 0.540 |
| Q3 '24 | 3.75B | 2.29B | 1.46B | 95M | 906M | 0.750 |
Insider Transactions View All
| Le Goff Corinne filed to sell 35,299 shares at $10.2. September 12 '25 |
| Smith Scott Andrew filed to buy 314,807 shares at $10. August 13 '25 |
| Smith Scott Andrew filed to buy 292,807 shares at $8.9. May 14 '25 |
| Campbell Paul filed to sell 126,901 shares at $12.9. November 12 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$243.71 0.5% | 57 |
 |
Eli Lilly and CompanyLLY |
$1001.35 0.7% | 62 |
 |
PfizerPFE |
$27.16 1.3% | 30 |
 |
AstrazenecaAZN |
$194.99 0% | 57 |
 |
AbbVieABBV |
$227.01 0.2% | 72 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Gil Cisneros |
Apr 8, 25 | Sell | $1K - $15K |
| Ro Khanna |
Dec 6, 24 | Buy | $1K - $15K |
| Rohit Khanna Democrat |
May 6, 24 | Buy | $1K - $15K |
Read more about Viatris (VTRS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Viatris
The Market Cap of Viatris is $16.3B.
As of today, Viatris' PE (Price to Earnings) ratio is 223.2.
Currently, the price of one share of Viatris stock is $14.08.
The VTRS stock price chart above provides a comprehensive visual representation of Viatris' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Viatris shares. Our platform offers an up-to-date VTRS stock price chart, along with technical data analysis and alternative data insights.
Yes, Viatris (VTRS) offers dividends to its shareholders, with a dividend yield of 3.3%. This dividend yield represents Viatris' commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Viatris in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
Some of the similar stocks of Viatris are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
